NAUT

Over the past six months, Nautilus Biotechnology's stock has experienced several notable events. The company reported its first-quarter 2026 earnings around April 28, beating consensus estimates. On July 28, 2026, Nautilus Biotechnology reported its second-quarter 2026 financial results, with an adjusted loss of $0.11 per share, surpassing the consensus estimate of $0.15 per share. During this period, the company announced a shift in its research and development focus towards proteoform assays and updated its commercial timelines, which led to a significant 28% drop in the stock price. In March 2026, Nautilus Biotechnology was the target of a substantial 51.1% increase in short interest from March 15th to March 31st. Around March 2026, the stock reached a new 52-week high. Also in March 2026, CEO Sujal Patel purchased 25,000 shares of the company's stock. Sentinel Trust Co. LBA acquired a new stake of 750,000 shares in Nautilus Biotechnology in the fourth quarter of 2025. A Nature Methods publication in September 2026 revealed deep insights into functional biology through the first-of-its-kind quantification of Tau Proteoforms, utilizing Nautilus's technology. In September 2026, Roth Capital initiated coverage of Nautilus Biotechnology with a 'Buy' rating. In early October 2026, the stock saw significant price movements, including a 24.84% increase on October 2, 2026. Overall, over the past six months, the stock has seen a decrease of 29.11%, but it has shown a 10.51% increase in the current year.